Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00194779
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:59.253656+00:00
Published At
2018-03-12T00:00:00+00:00
Record Updated At
2018-03-12
Results Posted At
2018-03-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-03-12"
protocolSection.identificationModule.nctId
"NCT00194779"
protocolSection.identificationModule.officialTitle
"A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-03-12"

Study condition terms

  • Estrogen Receptor-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage II Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.